MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras

Neuro-Oncology

Volumn 16, Issue 10, 2014, Pages 1341-1353

  Shi, Zhumei ^a   Chen, Qiudan ^a   Li, Chongyong ^a   Wang, Lin ^a   Qian, Xu ^a   Jiang, Chengfei ^a   Liu, Xue ^a   Wang, Xiefeng ^a   Li, Hai ^a   Kang, Chunsheng ^b   Jiang, Tao ^c   Liu, Ling Zhi ^d   You, Yongping ^a   Liu, Ning ^a   Jiang, Bing Hua ^a,d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Glioma; MiR 124; N Ras; R Ras

Indexed keywords

GUANOSINE TRIPHOSPHATASE; MICRORNA 124; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; R RAS PROTEIN; RAF PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; DACARBAZINE; MICRORNA; MIRN124 MICRORNA, HUMAN; RAS PROTEIN; RRAS PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CANCER RESISTANCE; CELL COUNTING; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ONCOGENE RAS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; VASCULARIZATION;

ANIMALS; APOPTOSIS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; GENES, RAS; GLIOMA; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84907959333     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou084     Document Type: Article

References (47)

1. Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther. 2001;1(3):395-401.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3 K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011;13(4):384-392.
4. Li RY, Chen LC, Zhang HY, et al. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther. 2013;19(7):477-483.
5. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522-531.
6. Long JM, Lahiri DK. Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. Exp Neurol. 2012;235(2):402-418.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
8. Zhang BG, Li JF, Yu BQ, et al. MicroRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep. 2012;27(4):1019-1026.
9. Ruan Q, Wang T, Kameswaran V, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U S A. 2011;108(29):12030-12035.
10. Zhang QQ, Xu H, Huang MB, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 2012;14(3):278-287.
11. An L, Liu Y, Wu A, Guan Y. MicroRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS One. 2013;8(7):e69478.
12. Wei J, Wang F, Kong LY, et al. MiR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013;73(13):3913-3926.
13. Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013;17(5):507-531.
14. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004;108(6):467-470.
15. Komatsu M, Ruoslahti E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med. 2005;11(12):1346-1350.
16. Nakada M, Niska JA, Tran NL, et al. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol. 2005;167(2):565-576.
17. Wang XR, Luo H, Li HL, et al. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro Oncol. 2013;15(11):1491-1501.
18. Kunz M. MicroRNAs in melanoma biology. Adv Exp Med Biol. 2013;774:103-120.
19. Cimino D, De Pitta C, Orso F, et al. MiR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J. 2013;27(3):1223-1235.
20. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143-2154.
21. Han Z, Yang Q, Liu B, et al. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis. 2012;33(1):131-139.
22. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308.
23. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes Dev. 2007;21(16):1989-1992.
24. Cole AL, Subbanagounder G, Mukhopadhyay S, et al. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol. 2003;23(8):1384-1390.
25. Santarpia L, Myers JN, Sherman SI, et al. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010;116(12):2974-2983.
26. Posch C, Moslehi H, Feeney L, et al. Combined targeting of MEK and PI3 K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013;110(10):4015-4020.
27. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.
28. Wang X. A PCR-based platform for microRNA expression profiling studies. RNA. 2009;15(4):716-723.
29. Sawada J, Urakami T, Li F, et al. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell. 2012;22(2):235-249.
30. Sandri C, Caccavari F, Valdembri D, et al. The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell Res. 2012;22(10):1479-1501.
31. Li Z, Zhang Y, Ramanujan K, et al. Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res. 2013;73(10):3041-3050.
32. Ohashi K, Sequist LV, Arcila ME, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013;19(9):2584-2591.
33. Wang C, Cigliano A, Delogu S, et al. Functional crosstalk between Akt/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle. 2013;12(13):1999-2010.
34. ChappellWH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3 K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2(3):135-164.
35. Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J. 2005;272(14):3491-3504.
36. Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and PI3 K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005;10:2986-3001.
37. Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis. 2007;28(4):858-864.
38. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(Suppl 616):15-18.
39. Yadav V, Denning MF. Fyn is induced by Ras/PI3 K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog. 2011;50(5):346-352.
40. Lee SH, Son MJ, Oh SH, et al. Thymosin {beta} (10) inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res. 2005;65(1):137-148.
41. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769-773.
42. Moller HG, Rasmussen AP, Andersen HH, et al. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol. 2013;47(1):131-144.
43. Blum R, Jacob-Hirsch J, Amariglio N, et al. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005;65(3):999-1006.
44. Zou C, Xu Q, Mao F, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012;11(11):2137-2145.
45. Gawecka JE, Griffiths GS, Ek-Rylander B, et al. R-Ras regulates migration through an interaction with filamin A in melanoma cells. PLoS One. 2010;5(6):e11269.
46. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635-647.
47. Lang MF, Yang S, Zhao C, et al. Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One. 2012;7(4):e36248.